AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
BioSpace17h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Yahoo Finance6d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
AbbVie was developing emraclidine to rival Bristol Myers’ Cobenfy (xanomeline and trospium chloride), also an oral medication for the treatment of schizophrenia in adults, which was approved by ...
Morningstar6d
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces a fundamentally new approach to treating schizophrenia by selectively ...
Yahoo Finance6d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
AbbVie was developing emraclidine to rival Bristol Myers’ Cobenfy (xanomeline and trospium chloride), also an oral medication for the treatment of schizophrenia in adults, which was approved by the ...
Investing6d
Bristol-Myers gets stock price target boost, rating held on Cobenfy outlook
Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian. Furthermore, BMS's Phase 3 EMERGENT-4 and EMERGENT-5 trials showed ...